TOP TEN perturbations for NM_000131 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000131
Selected probe(set): 207300_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000131 (207300_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)

Relative Expression (log2-ratio):-3.8897915
Number of Samples:3 / 11
Experimental HCC study 20 (CDX; Hep-G2; ectopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; ectopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.

HCC study 20 (CDX; Hep-G2; orthotopic) / HCC study 20 (PDX; orthotopic)

Relative Expression (log2-ratio):-2.6619568
Number of Samples:5 / 11
Experimental HCC study 20 (CDX; Hep-G2; orthotopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) orthotopically generated in SCID mice by injecting hepatocellular carcinoma cells directly into liver parenchyma. In order to establish orthotopic model, the left lobe of liver was exposed through midline abdominal incision and cells were injected directly into liver parenchyma of mice. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; orthotopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample orthotopically generated in SCID mice by injecting hepatocellular carcinoma cells directly into liver parenchyma. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish orthotopic model, the left lobe of liver was exposed through midline abdominal incision and cells were injected directly into liver parenchyma of mice. The mice were euthanized after two weeks.

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (10000 uM; Hep-G2) / vehicle (PBS) treated Hep-G2 cell sample

Relative Expression (log2-ratio):-2.616109
Number of Samples:3 / 6
Experimental 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (10000 uM; Hep-G2)
Hep-G2 cells exposed to 10000 uM 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (dissolved in PBS) for 72 hours. Cells were exposed to the chemical when 80% confluence was reached. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (PBS) treated Hep-G2 cell sample
Hep-G2 cells treated with vehicle (PBS) for 72 hours. Cells were exposed to the vehicle when 80% confluence was reached.

kidney transplantation study 12 (4 week) / normal T-cell (CD4+) sample

Relative Expression (log2-ratio):-2.4504585
Number of Samples:2 / 5
Experimental kidney transplantation study 12 (4 week)
CD4+ T-cell samples derived from kidney transplant patients 4 weeks post-transplantation. Samples were collected 4 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal T-cell (CD4+) sample
CD4+ T-cell samples derived from healthy control subjects.

4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG) / vehicle (DMSO) treated HepaRG cell sample

Relative Expression (log2-ratio):-2.3879423
Number of Samples:3 / 12
Experimental 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG)
HepaRG cells exposed to 7500 uM 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (dissolved in 0.5% v/v DMSO) for 72 hours. Cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Chemical was added at day 19 of cultivation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (DMSO) treated HepaRG cell sample
HepaRG cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Firstly, cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Then the vehicle was added.

clonidine study 5 (0.1 uM; HepaRG) / vehicle (DMSO) treated HepaRG cell sample

Relative Expression (log2-ratio):-2.2648973
Number of Samples:3 / 12
Experimental clonidine study 5 (0.1 uM; HepaRG)
HepaRG cells exposed to 0.1 uM clonidine (dissolved in 0.5% v/v DMSO) for 72 hours. Cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Chemical was added at day 19 of cultivation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:, , , ,
Control vehicle (DMSO) treated HepaRG cell sample
HepaRG cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Firstly, cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Then the vehicle was added.

kidney transplantation study 12 (pre) / normal T-cell (CD4+) sample

Relative Expression (log2-ratio):-2.0995207
Number of Samples:5 / 5
Experimental kidney transplantation study 12 (pre)
CD4+ T-cell samples derived from kidney transplant patients pre-transplantation. Samples were collected immediately before transplantation and administration of immunosuppressive therapy.
Control normal T-cell (CD4+) sample
CD4+ T-cell samples derived from healthy control subjects.

aflatoxin B1 study 2 (2.5 uM; HepaRG) / vehicle (DMSO) treated HepaRG cell sample

Relative Expression (log2-ratio):-1.9792948
Number of Samples:3 / 12
Experimental aflatoxin B1 study 2 (2.5 uM; HepaRG)
HepaRG cells exposed to 2.5 uM aflatoxin B1 (dissolved in 0.5% v/v DMSO) for 72 hours. Cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Chemical was added at day 19 of cultivation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (DMSO) treated HepaRG cell sample
HepaRG cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Firstly, cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Then the vehicle was added.

HCC study 18 (very advanced) / dysplastic liver nodule study 1

Relative Expression (log2-ratio):-1.8197975
Number of Samples:3 / 17
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control dysplastic liver nodule study 1
Dysplastic nodule tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.

2-(chloromethyl)pyridine hydrochloride study 1 (48h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):-1.7936249
Number of Samples:3 / 19
Experimental 2-(chloromethyl)pyridine hydrochloride study 1 (48h)
HepG2 cells exposed to 300?M 2-(chloromethyl)pyridine hydrochloride in DMSO solvent for 48 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 48 hours.